Beijing Correspondent, China
Based in Beijing, Zhuang Pinghui joined the Post in 2004 to report on China. She covers a range of issues including policy, healthcare, culture and society.
Latest from Zhuang Pinghui
The country currently has five candidate vaccines undergoing trials, four of which will need high levels of biosecurity to manufacture them safely.
Respiratory expert Zhong Nanshan says project with US epidemiologist Ian Lipkin to find source of virus is at risk.
Shi Zhengli tells state broadcaster that years of research meant cause of mystery pneumonia was quickly found after it emerged in Wuhan last year.
Gao Fu, head of the country’s Centre for Disease Control, says use could be fast-tracked for selected groups and in emergencies.
Premier Li Keqiang makes rare admission of failings as authorities look to strengthen monitoring and reporting system for infectious diseases.
Single dose of candidate medication yields antibodies in mice, researchers say.
As authorities battle to contain cluster in the northeast, experts say many people have ‘no background immunity’ and country is still facing big challenge.
Responding to claims by US Secretary of State Mike Pompeo, national health authority says this was done for biosafety reasons and to ‘prevent secondary disasters caused by unidentified pathogens’.
Migrant workers and the residents of rural areas are bearing the brunt of the employment crisis in China caused by Covid-19.
Authorities are easing the last of the country’s emergency restrictions but constant monitoring will be here for the longer term, they say.
Train and long-distance bus services halted, schools closed and gatherings banned as vice-mayor warns of ‘major risk of further spread’.
Millions of people to be tested for Covid-19 in 10-day campaign.
Police in Shaanxi province dug up 79-year-old from grave in woods after receiving tip-off.
Shulan in the northeastern province of Jilin says it is investigating source of infection after police employee comes down with Covid-19.
Various Chinese pharma firms are working on a way to inoculate against the new coronavirus but are struggling to test the potential vaccines under real conditions as the epidemic wanes at home.
The Wuhan Institute of Virology has been at the centre of a number of Covid-19 conspiracy theories, including one that the virus accidentally escaped.
City at centre of outbreak finally able to declare itself clear of disease after months in lockdown and thousands of deaths.
One of the vaccines in clinical trials could enter emergency use for groups such as health workers by September this year, official says.
Officials in Harbin have been punished for their handling of the case, in which an 87-year-old patient is thought to have infected 36 others.
Many studies halted ‘because no one expected that China would control the epidemic so quickly’, respiratory disease expert Zhong Nanshan says.
Medical products watchdog gives approval for clinical tests for two experimental preparations, with more expected to follow.
Medical crews sent to northern city to bolster health system overwhelmed with cases among people returning from Russia.
Protocols developed at the pandemic’s first hotspot could guide health care workers in the US and Europe as they struggle with the same issues.
Tianjin-based CanSino Biologics is recruiting 500 people for the second stage of the country’s main prospect for a preventive injection for Covid-19.
Retrospective look at patient samples finds slow build of coronavirus.
Advocate of the facilities in Wuhan suggests that home isolation of mild cases puts families at risk.
Estimated 1.4 million Chinese students remain overseas and most are electing to stay put as pandemic rages around the world.
Authorities in Yunnan limit land and river ports to cargo traffic, locking down border communities.
One doctor in Wuhan describes the emotional toll of trying to care for Covid-19 patients and warns that the most serious cases are still struggling to make it.